TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8726365

Group type: EXPERIMENTAL
Intervention: Rehearsing words 3 times
Number of subjects: 72

Group type: COMPARATOR
Intervention: Rehearsing words 1 time
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Speed of information processing measures (rehearsal time, articulation speed, DSST scores)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Task-independent speed of processing (DSST scores, articulation speed)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: DSST scores
Number of subjects: 72
Study: 1988077

Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg GM-CSF
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg GM-CSF
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg GM-CSF
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6880226

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g per day for 8 weeks followed by surgery if symptomatic recurrence occurs
Number of subjects: 100

Group type: COMPARATOR
Intervention: Repeated courses of cimetidine 1 g per day for 8 weeks in case of recurrence
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimetidine (either single course or repeated)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimetidine treatment (single vs repeated courses)
Number of subjects: 100
Study: 2876664

Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin 40 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin 40 mg/day and 80 mg/day
Number of subjects: 20
Study: 30054049

Group type: EXPERIMENTAL
Intervention: Single-agent cetuximab (Arm-A)
Number of subjects: 193

Group type: COMPARATOR
Intervention: mFOLFOX-6 + cetuximab (Arm-B)
Number of subjects: 193
Study: 28662222

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 652

Group type: COMPARATOR
Intervention: No systemic therapy
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: MammaPrint high risk
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: MammaPrint low risk
Number of subjects: 652
Study: 26353832

Group type: EXPERIMENTAL
Intervention: Bivalve cast
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pressure‐relieving ankle‐foot orthosis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study: 23830138

Group type: EXPERIMENTAL
Intervention: Merged Modules 1 and 2 (hip abductors and knee extensors during early stance, plantarflexors during late stance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Merged Modules 1 and 4 (hamstrings during late swing into early stance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General rehabilitation focus on plantarflexors
Number of subjects: 0
Study: 21196894

Group type: EXPERIMENTAL
Intervention: Open flap debridement plus bioactive glass (Perioglas)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Open flap debridement alone
Number of subjects: 8
Study: 18504550

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa activated (DAA)
Number of subjects: 7683

Group type: EXPERIMENTAL
Intervention: Confirmatory trial with DAA
Number of subjects: 7683

Group type: COMPARATOR
Intervention: Anti‐thrombin‐III
Number of subjects: 7683

Group type: COMPARATOR
Intervention: Tissue factor pathway inhibitor
Number of subjects: 7683
Study: 17061004

Group type: EXPERIMENTAL
Intervention: Social Norms Marketing (SNM) campaigns
Number of subjects: 2771

Group type: COMPARATOR
Intervention: Control group institutions
Number of subjects: 2771
Study: 12738312

Group type: EXPERIMENTAL
Intervention: Comet assay
Number of subjects: 65

Group type: COMPARATOR
Intervention: Eppendorf PO2 histograph
Number of subjects: 65
Study: 10770187

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg) for 5 yr (group I)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Alendronate (20 mg) for 2 yr followed by 3 yr off therapy (group III)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo for 3 yr followed by alendronate (5 mg) for 2 yr (group II)
Number of subjects: 447
Study: 9313386

Group type: EXPERIMENTAL
Intervention: Stress-management program
Number of subjects: 44
Study: 8393108

Group type: EXPERIMENTAL
Intervention: Doxycycline (Do) 200 mg on the first day and 100 mg for 4 days, followed by Amoxicillin/Clavulanate potassium (Au) 500 mg 3 times daily for 5 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Doxycycline (Do) for 10 days
Number of subjects: 11
Study: 3552892

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 28
Study: 30121688

Group type: EXPERIMENTAL
Intervention: Hydrocortisone-impregnated Gelfoam dressing
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal saline-impregnated Gelfoam dressing
Number of subjects: 8
Study: 27048836

Group type: EXPERIMENTAL
Intervention: Oral dietary supplementation of pasteurised Bacteroides xylanisolvens DSM 23964 for 8 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 24502652

Group type: EXPERIMENTAL
Intervention: Short-term professional oral health care (once per week for 1 month)
Number of subjects: 30
Study: 23564179

Group type: EXPERIMENTAL
Intervention: Oxytocin 40 IU nasal spray
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 16
Study: 20101370

Group type: EXPERIMENTAL
Intervention: TNK-facilitated PCI
Number of subjects: 170

Group type: COMPARATOR
Intervention: TNK alone
Number of subjects: 170
Study: 18847422

Group type: EXPERIMENTAL
Intervention: Biocompatible bicarbonate solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biocompatible lactate solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bicarbonate/lactate solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biocompatible solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialysis solutions with higher glucose degradation products
Number of subjects: 0
Study: 16635293

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment group (100 mg orally every day)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (conventional supporting treatment)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment group
Number of subjects: 164
Study: 14616259

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (2.2 g)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 698
Study: 10980913

Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (875 mg capsules containing 850 to 882 mg EPA and DHA)
Number of subjects: 11324

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 11324

Group type: EXPERIMENTAL
Intervention: Low-dose fish oil
Number of subjects: 11324

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 11324
Study: 9337948

Group type: EXPERIMENTAL
Intervention: Exposure and response prevention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Anxiety management
Number of subjects: 18
Study: 8473719

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3928960

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide with forced diuresis (Group A)
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-dose metoclopramide without forced diuresis (Group B)
Number of subjects: 11
Study: 31237044

Group type: EXPERIMENTAL
Intervention: ERG+ DLBCL
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Downregulation of miR-4638-5p
Number of subjects: 118

Group type: COMPARATOR
Intervention: ERG- DLBCL
Number of subjects: 118
Study: 28712475

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 111
Study: 25287626

Group type: EXPERIMENTAL
Intervention: e-SAID intervention (completed the e-SAID questionnaire)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (completed the same anxiety questions with a time-lapse)
Number of subjects: 168
Study: 23064290

Group type: EXPERIMENTAL
Intervention: GLP‐1(7‐37)amide (0.4 pmol min⁻¹ kg⁻¹)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study: 22134450

Group type: EXPERIMENTAL
Intervention: Sexual violence
Number of subjects: 4351

Group type: EXPERIMENTAL
Intervention: Witnessed violence
Number of subjects: 4351
Study: 19592388

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer (BP) stent
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Permanent polymer (PP; Cypher) stent
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Polymer-free (PF) stent
Number of subjects: 605
Study: 16875919

Group type: EXPERIMENTAL
Intervention: Extensive Lifestyle Management Intervention (ELMI)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study: 12631004

Group type: EXPERIMENTAL
Intervention: Grading scale of radiographic findings in the pubic bone and symphysis in athletes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group 1: 20 healthy age‐matched men
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group 2: 120 adults (66 men and 54 women) in 9 age groups between 15 and 90 years of age
Number of subjects: 20
Study: 11194264

Group type: EXPERIMENTAL
Intervention: Mentoring relationships
Number of subjects: 959

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 959
Study: 9177376

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg (n = 36, 29 completed)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg (n = 35, 28 completed)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (n = 20, 13 completed)
Number of subjects: 91
Study: 8257146

Group type: EXPERIMENTAL
Intervention: Rufloxacin taken 5 min after antacid (Maalox 30 ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rufloxacin taken 4 h before antacid (Maalox 30 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rufloxacin alone
Number of subjects: 12
Study: 4041513

Group type: EXPERIMENTAL
Intervention: nonsedating doses of diazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 30253049

Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid/Clobetasol Propionate Compound Ointment
Number of subjects: 240

Group type: COMPARATOR
Intervention: calcipotriol/betamethasone dipropionate ointment
Number of subjects: 240
Study: 26559681

Group type: EXPERIMENTAL
Intervention: B9 (10mg/day orally) for 2 months, followed by B12 (1000 μg) for 2 months, then B9 + B12 for 2 months (Group A)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: B12 for 2 months, followed by B9 for 2 months, then B9 + B12 for 2 months (Group B)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Wash-out period (t4) for both groups
Number of subjects: 132
Study: 24655701

Group type: EXPERIMENTAL
Intervention: Regional circulatory occlusion (RCO) during recovery after exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal recovery after exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RCO
Number of subjects: 11
Study: 22982080

Group type: EXPERIMENTAL
Intervention: Buried in Treasures (BIT) Workshop
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 21088807

Group type: EXPERIMENTAL
Intervention: L‐T4 replacement
Number of subjects: 23

Group type: COMPARATOR
Intervention: Simple observation (control)
Number of subjects: 23
Study: 17389557

Group type: EXPERIMENTAL
Intervention: darunavir (TMC114) coadministered with low-dose ritonavir under fasted conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: darunavir (TMC114) coadministered with low-dose ritonavir after a standard meal
Number of subjects: 0
Study: 16372585

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (SPFX) 200 mg/day for 21 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control treatment for 21 days
Number of subjects: 26
Study: 11953688

Group type: EXPERIMENTAL
Intervention: Octreotide 500 microg thrice daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9708456

Group type: EXPERIMENTAL
Intervention: IVUS-guided stent implantation (Group B)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard stent implantation without IVUS guidance (Group A)
Number of subjects: 155
Study: 9621317

Group type: EXPERIMENTAL
Intervention: Ultraviolet laser therapy (UVLT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ultraviolet irradiation (UVI)
Number of subjects: 16
Study: 1890604

Group type: EXPERIMENTAL
Intervention: AL 721 (20, 30, 40, or 50 g orally twice daily for 8 weeks)
Number of subjects: 40
Study: 6120718

Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cyclizine 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lactose (dummy control)
Number of subjects: 8
Study: 30702319

Group type: EXPERIMENTAL
Intervention: Negative mood condition
Number of subjects: 134

Group type: COMPARATOR
Intervention: Neutral mood condition
Number of subjects: 134
Study: 27640999

Group type: EXPERIMENTAL
Intervention: Alcoholic beer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-alcoholic beer
Number of subjects: 60
Study: 23811984

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Flexible Spectral Imaging Color Enhancement (FICE)
Number of subjects: 55
Study: 21272824

Group type: EXPERIMENTAL
Intervention: Text plus pictogram instructions
Number of subjects: 299

Group type: COMPARATOR
Intervention: Text-only instructions
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Text plus pictogram instructions (low health literacy)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Text-only instructions (low health literacy)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Text plus pictogram instructions (adequate health literacy)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Text-only instructions (adequate health literacy)
Number of subjects: 299
Study: 19688312

Group type: EXPERIMENTAL
Intervention: Qufeng Zhidong Recipe (QZR)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Haloperidol plus trihexyphenidyl (WM group)
Number of subjects: 81
Study: 17578709

Group type: EXPERIMENTAL
Intervention: Propranolol (n = 7)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Neurogenic blockade (n = 8)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Phentolamine (n = 8)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Mental stress without intervention (n = 8)
Number of subjects: 31
Study: 15180776

Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioural Therapy (CBT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Group Psychoeducation (PE)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both CBT and PE
Number of subjects: 88
Study: 11497156

Group type: EXPERIMENTAL
Intervention: High-volume haemofiltration (HVHF; 6 l/h)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard continuous veno-venous haemofiltration (CVVH; 1 l/h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both therapies (HVHF and CVVH)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-volume haemofiltration (HVHF)
Number of subjects: 11
Study: 9228314

Group type: COMPARATOR
Intervention: Interference screw fixation (n = 40)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Staple fixation (n = 15)
Number of subjects: 55
Study: 8221579

Group type: EXPERIMENTAL
Intervention: Daunorubicin infusion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Daunorubicin bolus
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MSK‐NY‐II protocol
Number of subjects: 44
Study: 2829323

Group type: EXPERIMENTAL
Intervention: Initial assessment of patients with small cell lung cancer
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Fibroscopy as the main diagnostic method
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Thoracotomies
Number of subjects: 304
Study: 30289006

Group type: EXPERIMENTAL
Intervention: Thermogenic dietary supplement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29873709

Group type: EXPERIMENTAL
Intervention: Achieved diastolic blood pressure (DBP) <70 mmHg
Number of subjects: 16099

Group type: EXPERIMENTAL
Intervention: Achieved DBP ≥80 mmHg
Number of subjects: 16099

Group type: COMPARATOR
Intervention: Achieved DBP 70 to <80 mmHg
Number of subjects: 16099

Group type: EXPERIMENTAL
Intervention: Achieved DBP ≥90 mmHg
Number of subjects: 16099
Study: 27723225

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 641

Group type: COMPARATOR
Intervention: NPH
Number of subjects: 641
Study: 24915899

Group type: EXPERIMENTAL
Intervention: FOLFIRI+PB (panitumumab 3 mg/kg and bevacizumab 3 mg/kg plus FOLFIRI every other week)
Number of subjects: 292

Group type: COMPARATOR
Intervention: FOLFIRI (FOLFIRI only)
Number of subjects: 292
Study: 22854402

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D) 50,000 IU/wk for 12 weeks followed by 50,000 IU every other week for 40 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 20534318

Group type: EXPERIMENTAL
Intervention: Traditional chiropractic manipulation (lumbar roll technique with a pisiform contact on the ipsilateral mamillary of L5)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham group (same technique used, but no thrust applied)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Traditional chiropractic manipulation
Number of subjects: 20
Study: 18480726

Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-bundle reconstruction (anteromedial bundle)
Number of subjects: 0
Study: 15897728

Group type: EXPERIMENTAL
Intervention: Alcohol condition (target blood alcohol level of 0.08%)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 48
Study: 12689743

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Doxazosin and Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10476945

Group type: EXPERIMENTAL
Intervention: Sublingual human interferon-alpha (IFN-alpha) 15 IU
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Sublingual human interferon-alpha (IFN-alpha) 150 IU
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 8701785

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cyproterone acetate (100 mg on days 5-14 of the menstrual cycle)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cyproterone acetate
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Flutamide and Cyproterone acetate
Number of subjects: 22
Study: 1676507

Group type: EXPERIMENTAL
Intervention: Neuroleptic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 6418100

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Quinidine (700 to 1100 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Disopyramide (600 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Amiodarone (often associated with Class I antiarrhythmics)
Number of subjects: 44
Study: 30684213

Group type: EXPERIMENTAL
Intervention: Nurse home visiting intervention
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Paraprofessional home visiting intervention
Number of subjects: 735

Group type: COMPARATOR
Intervention: Control group (screening and referral for behavioral and developmental problems)
Number of subjects: 735
Study: 29753661

Group type: COMPARATOR
Intervention: Protocol 1 (P1) with 120 kVp, 180mAs, and 100mL of contrast agent with filtered back‐projection (FBP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Protocol 2 (P2) with 80 kVp, 140mAs and 75mL of contrast agent with hybrid iterative reconstruction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Protocol 3 (P3) with 80 kVp, 140mAs and 75mL of contrast agent with iterative model reconstruction (IMR)
Number of subjects: 60
Study: 26902276

Group type: EXPERIMENTAL
Intervention: microRNA‐146a enhancement group
Number of subjects: 12

Group type: COMPARATOR
Intervention: microRNA‐146a inhibition group
Number of subjects: 12

Group type: COMPARATOR
Intervention: microRNA control group
Number of subjects: 12
Study: 25465181

Group type: EXPERIMENTAL
Intervention: Strontium‐90 beta radiotherapy (50 Gy)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham radiotherapy
Number of subjects: 10
Study: 21945922

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 0
Study: 19073624

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study: 17994514

Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Formulation B
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Formulation C
Number of subjects: 38
Study: 15998607

Group type: EXPERIMENTAL
Intervention: ODIN program with postcard reminders (n = 75)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: ODIN program with telephone reminders (n = 80)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Treatment as usual control group without access to the ODIN website (n = 100)
Number of subjects: 255
Study: 17943671

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted socket
Number of subjects: 9
Study: 9614619

Group type: EXPERIMENTAL
Intervention: Pramlintide 30 micrograms q.i.d.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pramlintide 60 micrograms t.i.d.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pramlintide 60 micrograms q.i.d.
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 8597466

Group type: EXPERIMENTAL
Intervention: DHEA 300 mg, orally three times daily for 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo capsule, orally three times daily for 14 days
Number of subjects: 10